Chlamydia vaccine candidate: Safe and able to provoke an immune response in Phase 1 trial
by Press Release from Outbreak News Today on (#4N5KV)
Chlamydia is the most common sexually transmitted bacterial infection worldwide, but national screening programs and antibiotic treatment have failed to decrease infection incidences. The first ever chlamydia vaccine to reach phase 1 clinical trial has been found to be safe and able to provoke an immune response, according to a study published in The Lancet Infectious ["]
The post Chlamydia vaccine candidate: Safe and able to provoke an immune response in Phase 1 trial appeared first on Outbreak News Today.